Although mechanisms of acquired resistance, such as T790M secondary mutation and MET amplification, have recently been found, other mechanisms should be identified to widen the therapeutic strategy for NSCLC with EGFR mutations (38,39). The gene discussed is MET; the disease is non-small cell lung carcinoma.